{"id":8063,"date":"2025-04-16T16:46:46","date_gmt":"2025-04-16T08:46:46","guid":{"rendered":"https:\/\/chimebiologics.com\/?p=8063"},"modified":"2025-06-16T15:40:07","modified_gmt":"2025-06-16T07:40:07","slug":"chime-biologics-partners-polpharma-biologics-to-advance-global-biosimilar-development","status":"publish","type":"post","link":"https:\/\/chimebiologics.com\/ja\/chime-biologics-partners-polpharma-biologics-to-advance-global-biosimilar-development\/","title":{"rendered":"(English) Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development"},"content":{"rendered":"<p class=\"qtranxs-available-languages-message qtranxs-available-languages-message-ja\">\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000<a href=\"https:\/\/chimebiologics.com\/en\/wp-json\/wp\/v2\/posts\/8063\" class=\"qtranxs-available-language-link qtranxs-available-language-link-en\" title=\"English\">English<\/a>\u3068 <a href=\"https:\/\/chimebiologics.com\/zh\/wp-json\/wp\/v2\/posts\/8063\" class=\"qtranxs-available-language-link qtranxs-available-language-link-zh\" title=\"\u4e2d\u6587\">\u4e2d\u6587<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p><style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8\">\n.flex_column.av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8{\n-webkit-border-radius:0px 0px 0px 0px;\n-moz-border-radius:0px 0px 0px 0px;\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div class='flex_column av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8 av_two_third  avia-builder-el-0  el_before_av_one_third  avia-builder-el-first  first flex_column_div av-zero-column-padding '     ><section  class='av_textblock_section av-mbsqh684-fc0f4f92bd503bd0df82f5b66a893bad'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><div class=\"mceTemp\"><\/div>\n<p><\/p>\n<\/div><\/section><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2d3l4o-9301d0cdc14489efa114080353995aa9\">\n.flex_column.av-2d3l4o-9301d0cdc14489efa114080353995aa9{\n-webkit-border-radius:0px 0px 0px 0px;\n-moz-border-radius:0px 0px 0px 0px;\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div class='flex_column av-2d3l4o-9301d0cdc14489efa114080353995aa9 av_one_third  avia-builder-el-2  el_after_av_two_third  el_before_av_one_full  flex_column_div av-zero-column-padding '     ><\/div><\/p>\n<div class='flex_column av-av_one_full-7714eba142aeda1f8b5272a3c372b279 av_one_full  avia-builder-el-3  el_after_av_one_third  el_before_av_textblock  first flex_column_div column-top-margin'     ><\/div>\n<section  class='av_textblock_section av-k6j2pxor-09272cddfdcc1afe6211303b3b3d55e0'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><p><\/p>\n<h1><strong>Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development<\/strong><\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-8086 aligncenter\" src=\"https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF.jpeg\" alt=\"\" width=\"1179\" height=\"498\" srcset=\"https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF.jpeg 1179w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF-300x127.jpeg 300w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF-1030x435.jpeg 1030w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF-768x324.jpeg 768w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2025\/04\/FA65EE42-4EAE-42AA-A4AF-05C6C81BEDAF-705x298.jpeg 705w\" sizes=\"auto, (max-width: 1179px) 100vw, 1179px\" \/><\/p>\n<ul>\n<li><em>Accelerate Polpharma Biologics biosimilar program from IND to commercial manufacturing<\/em><\/li>\n<li><em>Includes a commitment to producing for US FDA BLA submission<\/em><\/li>\n<li><em>Expand global market presence through launch in EU and other regions<\/em><\/li>\n<\/ul>\n<p><strong>April 16, 2025, Gda\u0144sk, Poland and Shanghai, China \u2013<\/strong> <a href=\"http:\/\/www.chimebiologics.com\">Chime Biologics<\/a>, a leading global CDMO that enables its partners' success in biologics, is pleased to announce a strategic cooperation agreement with <a href=\"https:\/\/polpharmabiologics.com\/en\/\">Polpharma Biologics<\/a> to advance the end-to-end development and manufacture of a biosimilar product for the global market. This partnership underscores Chime Biologics' commitment to delivering high-quality, cost-effective biologics and further strengthening Chime Biologics\u2019 presence in Europe.<\/p>\n<p>Under this agreement, Chime Biologics will provide Polpharma Biologics with end-to-end\u00a0support for a biosimilar development, spanning from investigational new drug (IND) to commercial supply.<\/p>\n<p><strong>Meeting Global Supply Needs<\/strong><\/p>\n<p>Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland, brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along with two FDA\/EMA-approved biosimilar products.<\/p>\n<p>With an extensive track record in delivering biosimilars for global markets, Chime Biologics is well-positioned to meet the growing global demand for biosimilars. Through Chime's true end to end offerings, from our state-of-the-art cell line, process and analytical development capabilities, expanding manufacturing capabilities and regulatory support activities, Chime Biologics offers clients fast-tracked CMC development to commercial supply to ensure fast market entry for our clients.<\/p>\n<p>\"We are thrilled to contribute to Polpharma Biologics' growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market,\" said <strong>Dr. Jimmy Wei, President of Chime Biologics<\/strong>. \"This collaboration reinforces our strategy of delivering high-quality, affordable biologics to patients worldwide.\"<\/p>\n<p>\"Partnering with Chime Biologics supports our strategic vision to swiftly bring affordable biosimilars developed in Europe to global markets,\" said<strong> Konstantin Matentzoglu, Member of the Supervisory Board of Polpharma Biologics Group BV<\/strong>. \u201cBy working with Chime Biologics, we can accelerate patient access to biosimilar therapies. This partnership further strengthens Polpharma Biologics\u2019 global position as a leading biosimilars developer, while leveraging Asian partners with optimized cost-benefit ratio\".<\/p>\n<p><strong>About Polpharma Biologics<\/strong><\/p>\n<p>Polpharma Biologics is an international biotechnology company, with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Polpharma Biologics develops biosimilar therapies to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production, preparing drugs for future commercial partnerships with global pharmaceutical organizations. Under partnerships agreements, the company manufactures two approved biosimilars from its pipeline; ranibizumab and natalizumab. With its cell line development center in The Netherlands, and two centers of development and manufacturing in Poland, Polpharma Biologics creates development opportunities for biotechnology specialists. For more information, please visit <a href=\"https:\/\/polpharmabiologics.com\/en\/\">https:\/\/polpharmabiologics.com\/en\/<\/a>.<\/p>\n<p><strong>About Chime Biologics<\/strong><\/p>\n<p>Chime Biologics is a leading global CDMO, focused on ensuring its partners\u2019 success in delivering innovative biologics to the world. Chime Biologics is a biologics service provider, from pre-clinical support and cell line development to clinical and commercial manufacturing of DS and DP. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the global biologics industry. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling our commitment to human health. For more information, please visit<a href=\"https:\/\/chimebiologics.com\/\">\u00a0www.chimebiologics.com<\/a>.<\/p>\n<p><\/p>\n<div class=\"mceTemp\"><\/div>\n<\/div><\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":8086,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46,52],"tags":[],"class_list":["post-8063","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-news","category-news"],"_links":{"self":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/8063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/comments?post=8063"}],"version-history":[{"count":20,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/8063\/revisions"}],"predecessor-version":[{"id":8773,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/8063\/revisions\/8773"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/media\/8086"}],"wp:attachment":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/media?parent=8063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/categories?post=8063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/tags?post=8063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}